Newsletter | August 8, 2025

08.08.25 -- Epigenetic Editing Is Revolutionizing Genetic Medicine

SPONSOR

Partnerships with Sites, held September 15, 2025, in Philadelphia, is purpose-built for clinical operations professionals looking to elevate collaboration with research sites. Through real-world case studies and strategic discussions, attendees will gain tools to reduce burden, accelerate enrollment, and build stronger sponsor-site relationships. Use code LSL20 for 20% off your registration.

FEATURED PODCAST

BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies

This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling gene expression, without cutting DNA like traditional CRISPR technologies.

INDUSTRY INSIGHTS

Key Strategies For Clinical Development In Rare Cancers

Successful execution of rare cancer clinical trials requires strategic patient recruitment, innovative trial design, and specialized expertise from Oncology CROs.

Process Intensification: Key Considerations And Expert Insights

Experts share their experiences implementing process intensification to provide a holistic perspective and the top considerations for your internal calculations, deliberations, and decision-making.

RTP Company Advancing Sample Prep Through Microfluidics Technology

Discover how Redbud Labs is revolutionizing sample preparation with cutting-edge microfluidics technology and their innovative platform that enhances laboratory efficiency.

Accelerating Clinical Data Review With Traceable Workflows

Explore how streamlined workflows and enhanced collaboration between data managers and medical reviewers can boost clinical trial efficiency, improve data quality, and ensure patient safety.

Striking A Balance Of Speed And Quality To Deliver Next-Gen Therapeutics

Successful delivery of a bispecific antibody therapeutic to patients necessitates a manufacturing strategy that can accommodate the unique size, structure, and complexity of these molecules to ensure quality.

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.